Modification of antigenicity for cancer cells by foreign peptide decoration by using hyaluronic acid
| Project/Area Number |
18K12082
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 90120:Biomaterials-related
|
|---|
| Research Institution | The University of Kitakyushu |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Keywords | 薬物送達システム / がんワクチン / 多糖 / 抗原提示 / 抗原 / 免疫療法 / 糖鎖 / 抗原ペプチド |
|---|
| Outline of Final Research Achievements |
The prepared conjugates consisting of hyaluronic acid (HA) and ovalbumin (OVA) are incorporated into cancer cells through HA receptor CD44. When cancer cells treated with HA-OVA conjugates and splenocytes immunized with OVA and adjuvants, strong immune responses were observed. These results indicate OVA fragments are presented on the cancer cellular surface, and we succeeded in modification of cancer antigenicity.
|
| Academic Significance and Societal Importance of the Research Achievements |
チェックポイント阻害剤等による免疫抑制が解除されたのち、実際に腫瘍を縮退させるのは患者がもともと体内に持っている免疫力、つまり細胞傷害性Ｔ細胞（CTL）の力である。CTLが十分に能力を発揮させるための技術開発は、がん免疫療法を次のステージに発展させる鍵と考えられる。その中で、本提案の抗原性改変技術はがんワクチンに対する新たな戦略の一つになり得ると確信している。
|
Report
(4 results)
Research Products
(22 results)
